X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK LTD TORRENT PHARMA/
MERCK LTD
 
P/E (TTM) x 44.7 46.0 97.2% View Chart
P/BV x 6.3 6.9 90.9% View Chart
Dividend Yield % 0.8 0.4 199.4%  

Financials

 TORRENT PHARMA   MERCK LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
MERCK LTD
Dec-16
TORRENT PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,5501,060 146.2%   
Low Rs1,144623 183.5%   
Sales per share (Unadj.) Rs354.7632.4 56.1%  
Earnings per share (Unadj.) Rs40.145.7 87.7%  
Cash flow per share (Unadj.) Rs64.262.3 103.1%  
Dividends per share (Unadj.) Rs14.0011.00 127.3%  
Dividend yield (eoy) %1.01.3 79.5%  
Book value per share (Unadj.) Rs273.1388.8 70.2%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.3 285.4%   
Avg P/E ratio x33.618.4 182.6%  
P/CF ratio (eoy) x21.013.5 155.3%  
Price / Book Value ratio x4.92.2 227.8%  
Dividend payout %34.924.1 145.2%   
Avg Mkt Cap Rs m227,89713,969 1,631.5%   
No. of employees `00014.71.6 928.6%   
Total wages/salary Rs m11,3531,487 763.6%   
Avg. sales/employee Rs Th4,083.06,631.9 61.6%   
Avg. wages/employee Rs Th772.3939.2 82.2%   
Avg. net profit/employee Rs Th461.3479.4 96.2%   
INCOME DATA
Net Sales Rs m60,02110,498 571.7%  
Other income Rs m2,988242 1,232.8%   
Total revenues Rs m63,00910,741 586.6%   
Gross profit Rs m13,4931,135 1,188.5%  
Depreciation Rs m4,086276 1,483.1%   
Interest Rs m3,0850-   
Profit before tax Rs m9,3101,102 844.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529343 736.6%   
Profit after tax Rs m6,781759 893.6%  
Gross profit margin %22.510.8 207.9%  
Effective tax rate %27.231.1 87.2%   
Net profit margin %11.37.2 156.3%  
BALANCE SHEET DATA
Current assets Rs m52,6236,410 821.0%   
Current liabilities Rs m52,0228,828 589.3%   
Net working cap to sales %1.0-23.0 -4.3%  
Current ratio x1.00.7 139.3%  
Inventory Days Days12058 207.3%  
Debtors Days Days7638 198.6%  
Net fixed assets Rs m85,0161,406 6,045.0%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m45,3766,286 721.9%   
Net worth Rs m46,2226,455 716.1%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4328,828 1,613.4%  
Interest coverage x4.0NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.2 35.4%   
Return on assets %6.98.6 80.6%  
Return on equity %14.711.8 124.8%  
Return on capital %14.217.1 83.1%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m14,580959 1,520.7%   
Fx outflow Rs m3,6002,612 137.8%   
Net fx Rs m10,980-1,653 -664.2%   
CASH FLOW
From Operations Rs m8,9421,070 835.4%  
From Investments Rs m-47,070-750 6,278.4%  
From Financial Activity Rs m34,174-150 -22,813.0%  
Net Cashflow Rs m-3,655171 -2,138.7%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 25, 2018 03:37 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS